1. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways
   Igor Hrgovic et al, 2016, BMC Cancer CrossRef
2. Zinc-Dependent Histone Deacetylases in Lung Endothelial Pathobiology
   Rahul S. Patil et al, 2024, Biomolecules CrossRef
3. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations
   Alexander J. Osborn et al, 2015, Human Molecular Genetics CrossRef
4. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
   Pierre Autin et al, 2019, Cancers CrossRef
5. Epigenetic therapies: histone deacetylases
   Christophe Blanquart, 2023, Epigenetic Cancer Therapy CrossRef
6. Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network
   T.V. Shiva Shankar et al, 2014, Vascular Pharmacology CrossRef
7. Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
   Xiaona Chen et al, 2020, Frontiers in Cell and Developmental Biology CrossRef
8. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
   Massimiliano Cadamuro et al, 2017, International Journal of Molecular Sciences CrossRef
9. Epigenetic Metalloenzymes
   Christophe Blanquart et al, 2019, Current Medicinal Chemistry CrossRef
10. Recent Progress in Lymphangioma
    Xiaowei Liu et al, 2021, Frontiers in Pediatrics CrossRef